Develops and markets the BVA-100 Blood Volume Analyzer. Provides diagnostic blood tests for quantifying blood volume status. Now — the numbers.
This is an established company with proven profits.
The gap is $112K. In times of high interest rates, a gap like that can squeeze a company.
The market pays 7.3× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
Against companies in its own sector, it looks cheaper than 66% of them.
Analysts' average target sits 101% above today's price.
Buys outnumber sells, but taken together the trades don’t add up to a strong signal of confidence.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly above the class average — a step short of the very top.
This grade is a blend: the profit side is strong, the sales tempo slow.
The price is looking for direction — no strong breakout, no collapse.
No real weak spot in any of the five subjects — a balanced report card.
The stock trades 22% below its peak. The market has trimmed its expectations for the company.
Our checks did not surface a specific strength to highlight here.
Over the last 2 years, sales fell about 88% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
Since the drop from its peak, buyer appetite hasn’t come back.
As the slice kept from each sale thins out, so does the profit.
On our five-subject report card, DXR sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: DXR does earn real profits — but on our report card it still sits behind its class. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Not covered, because the filings we hold do not carry it: the growth trend, earnings execution, the revenue breakdown.